Menu
← Oncology Approval Tracker
FDA DECISION ·
Talvey
talquetamab-tgvs · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory multiple myeloma after at least four treatment lines, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 antibody.
LAMPGEN ANALYSIS
Why it matters
This accelerated approval introduced a GPRC5D-directed T-cell engager for heavily pretreated myeloma.
What research teams should watch
Plan step-up dosing, toxicity observation and follow-up for oral and nutritional effects.
PRIMARY RECORDS